Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Accounts Payable
Gensight Biologics SA
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Accounts Payable
€4.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Accounts Payable
€42.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Accounts Payable
€24.6m
|
CAGR 3-Years
30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accounts Payable
€30.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
14%
|
|
|
Inventiva SA
PAR:IVA
|
Accounts Payable
€36.6m
|
CAGR 3-Years
53%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Accounts Payable
€12.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
31%
|
CAGR 10-Years
13%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Accounts Payable?
Accounts Payable
4.8m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Accounts Payable amounts to 4.8m EUR.
What is Gensight Biologics SA's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-4%
Over the last year, the Accounts Payable growth was -58%. The average annual Accounts Payable growth rates for Gensight Biologics SA have been -6% over the past three years , -4% over the past five years .
You don't have any saved screeners yet